Brand-name drug
Caplyta price, strengths & recalls
Brand of lumateperone (generic)
Pharmacies pay $1,717.21 for 30 capsules of Caplyta 42 mg capsule this week, and from $1,716.07 to $1,717.21 across its 3 priced strengths and forms. Its official label last changed on November 9, 2026.
Brand- Fair cash price
- $1,985.29
- Strengths
- 3
- Makers
- 1
- Updated
- Nov 11
Caplyta price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 10.5 mg capsule Brand | $57.22 | $1,716.52 / 30 capsules |
| 21 mg capsule Brand | $57.20 | $1,716.07 / 30 capsules |
| 42 mg capsule Brand | $57.24 | $1,717.21 / 30 capsules |
The lowest cost per capsule is 21 mg capsule at $57.20. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Caplyta vs generic lumateperone
There is no generic version of Caplyta on the market yet. Its last listed patent or exclusivity runs to December 10, 2040 - generics often follow, though court cases and settlements can move the date either way.
GenericLumateperone pricesSupply status: shortages & recalls
What people paid for Caplyta
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use CAPLYTA safely and effectively. See full prescribing information for CAPLYTA. CAPLYTA® (lumateperone) capsules, for oral use Initial U.S. Approval: 2019
WARNING:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL
THOUGHTS AND BEHAVIORS
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)].
Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.2)]. The safety and effectiveness of CAPLYTA have not been established in pediatric patients [see Use in Specific Populations (8.4)].
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. (5.1)
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of CAPLYTA have not been established in pediatric patients. (5.2, 8.4)
Recent major changes (as listed on the label)
Indications and Usage, adjunctive treatment of major depressive disorder (1)
| 11/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA209500 · Intra-Cellular
- First approved
- December 20, 2019 (7 years ago)
- Latest approved change
- April 24, 2026
- Approved label
- PDF, Apr 28, 2026
- Generic makers
- None on the market
- Last patent listed
- December 10, 2040
- Exclusivity ends
- April 24, 2029
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Caplyta questions
How much does caplyta cost without insurance?
Pharmacies pay about $1,717.21 for 30 capsules of caplyta 42 mg capsule ($57.24 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,985.29. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Caplyta?
Yes: lumateperone. Compare lumateperone prices.
Is caplyta in shortage?
No shortage is reported for caplyta right now. We check the national shortage list every day.
Has caplyta been recalled?
No recalls are on record for caplyta.
When did the caplyta label last change?
The official label was last updated on November 9, 2026 (version 28). See what changed.
Talk about caplyta
No comments yet. Questions, tips, what worked for you - start the conversation.